Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present BioCorRx Inc. (OTC: BICX).

Full DD Report for BICX

You must become a subscriber to view this report.


Recent News from (OTC: BICX)

BioCorRx reports Q2 results
BioCorRx ( OTCQB:BICX ): Q2 EPS of $0.00 More news on: BioCorRx Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 15 2018 08:09
BioCorRx Provides Business Update for the Second Quarter of 2018
ANAHEIM, CA, Aug. 15, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update for the second quarter ended June 30, 2018. Second Qua...
Source: GlobeNewswire
Date: August, 15 2018 08:00
BioCorRx Provides Update on BICX102
ANAHEIM, CA, Aug. 07, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced a general update on BICX102, the Company’s sustained release n...
Source: GlobeNewswire
Date: August, 07 2018 07:30
Brady Grainer, CEO of BioCorRX Inc. Joins Everett Jolly on "Stock Day"
PHOENIX, Ariz., July 24, 2018 (GLOBE NEWSWIRE) -- Uptick Newswire, today announced the return of BradyGrainer, CEO of BioCorRX Inc. to Uptick Newswire’s Stock Day podcast with Everett Jolly. The Company is a developer and provider of advanced solutions in the treatment of alcohol and...
Source: GlobeNewswire
Date: July, 24 2018 08:00
Your Daily Pharma Scoop: Secondaries Review June 4-11
A discussion of secondary offerings provides interesting analysis of a company. There are two kinds of secondary offerings; one, the non-dilutive kind, where no new shares are issued, but a large institutional shareholder simply releases a large block of previously issued shares. Two, a diluti...
Source: SeekingAlpha
Date: June, 12 2018 10:00
BioCorRx Raises $1.1 Million at Premium to Market
ANAHEIM, CA, June 06, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced the Company recently sold 5.5 million shares of common stock in a pri...
Source: GlobeNewswire
Date: June, 06 2018 07:00
BioCorRx Announces Grant Submission to the National Institutes of Health for BICX102
ANAHEIM, CA, May 22, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced it has submitted a grant application to the National Institutes of Hea...
Source: GlobeNewswire
Date: May, 22 2018 07:30
BioCorRx Provides Business Update for the First Quarter of 2018
ANAHEIM, CA, May 21, 2018 (GLOBE NEWSWIRE) -- BioCorRx, Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use disorders, today provided a business update for the first quarter ended March 31, 2018. First Quarte...
Source: GlobeNewswire
Date: May, 21 2018 07:30
BioCorRx Gains Additional Media Coverage from Fox Medical Correspondent Who Discusses the Advantages of the Naltrexone Implant
ANAHEIM, CA, April 30, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company") , a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today reported that Dr. Mark Siegel, commented on the advantages of sustained relea...
Source: GlobeNewswire
Date: April, 30 2018 07:00
BioCorRx CEO Brady Granier and Actor Jeremy Miller Appear on Varney & Co. on Fox Business to Discuss the Company's Sustained Release Naltrexone Implant for Alcohol Use Disorder
ANAHEIM, CA, April 26, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company") , a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that Brady Granier, BioCorRx CEO, President, and Director, as ...
Source: GlobeNewswire
Date: April, 26 2018 08:47

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-140.0750.070.0750.068108,175
2018-12-130.0780.070.0780.07233,050
2018-12-120.07750.0720.0780.072113,700
2018-12-110.0770.0770.07750.0651496,003
2018-12-100.07780.07790.0780.0732255,360

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1341,000233,05017.5928Cover
2018-12-1221,280113,70018.7159Cover
2018-12-1116,900496,0033.4072Cover
2018-12-1080,944255,36031.6980Cover
2018-12-0741,01596,61542.4520Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BICX.


About BioCorRx Inc. (OTC: BICX)

Logo for BioCorRx Inc. (OTC: BICX)

BioCorRx Inc. is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx amp reg Recovery Program, a non addictive, medication assisted treatment MAT program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one on one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long term naltrexone treatment. The Company also has an R amp amp D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit www.BioCorRx.com.

 

 

 

Current Management

  • Brady Granier / CEO, President
  • Lourdes Felix / CFO, COO
  • Tom Welch / VP, Ops.
  • Kent Emry / Chairman, Independent Director
  • Lourdes Felix /
  • Brady Granier /

Current Share Structure

  • Market Cap: $34,431,080 - 03/16/2018
  • Authorized: 525,000,000 - 03/01/2018
  • Issue and Outstanding: 245,936,285 - 03/01/2018
  • Float: 110,031,021 - 06/27/2016

 


Recent Filings from (OTC: BICX)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 16 2018
Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: May, 15 2018
All other definitive information statements
Filing Type: DEF 14CFiling Source: edgar
Filing Date: April, 10 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 05 2018
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: April, 02 2018
Information statements. Revised preliminary material
Filing Type: PRER14CFiling Source: edgar
Filing Date: March, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 01 2018
Preliminary proxy statement containing all other information
Filing Type: PRE 14CFiling Source: edgar
Filing Date: February, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 01 2018

 

 


Daily Technical Chart for (OTC: BICX)

Daily Technical Chart for (OTC: BICX)


Stay tuned for daily updates and more on (OTC: BICX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BICX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BICX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of BICX and does not buy, sell, or trade any shares of BICX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/